Thus, CD40 inhibition by treatment with specific inhibitors such as monoclonal antibodies, CDX-1140, and Dacetuzumab can inhibit the pathways induced by CD40 in AML patients and improve treatment outcomes [175–177]. The gene discussed is CD40; the disease is acute myeloid leukemia.